Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United Stat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/1758835918788310 |
| _version_ | 1828433815707582464 |
|---|---|
| author | Pooja Ghatalia Matthew Zibelman Daniel M. Geynisman Elizabeth Plimack |
| author_facet | Pooja Ghatalia Matthew Zibelman Daniel M. Geynisman Elizabeth Plimack |
| author_sort | Pooja Ghatalia |
| collection | DOAJ |
| description | The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United States Food and Drug Administration (FDA) approved. In cisplatin-ineligible patients, atezolizumab and pembrolizumab are the FDA-approved checkpoint inhibitors. Here we describe the updated clinical efficacy of these checkpoint inhibitors in the treatment of advanced urothelial carcinoma and then suggest how they can be sequenced in the context of available chemotherapeutic options. For cisplatin-eligible patients, platinum-based chemotherapy remains the standard first-line treatment. For patients progressing on platinum-based therapy, phase III trials have been performed comparing pembrolizumab and atezolizumab separately with standard chemotherapy, and results favor the use of pembrolizumab. |
| first_indexed | 2024-12-10T18:41:04Z |
| format | Article |
| id | doaj.art-8b9ee381ca394505b5ea4c5a8f2f2424 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-12-10T18:41:04Z |
| publishDate | 2018-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-8b9ee381ca394505b5ea4c5a8f2f24242022-12-22T01:37:39ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592018-07-011010.1177/1758835918788310Approved checkpoint inhibitors in bladder cancer: which drug should be used when?Pooja GhataliaMatthew ZibelmanDaniel M. GeynismanElizabeth PlimackThe treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of five checkpoint inhibitors. In the second-line setting, in patients who have progressed on cisplatin-based chemotherapy, pembrolizumab, atezolizumab, durvalumab, nivolumab and avelumab are United States Food and Drug Administration (FDA) approved. In cisplatin-ineligible patients, atezolizumab and pembrolizumab are the FDA-approved checkpoint inhibitors. Here we describe the updated clinical efficacy of these checkpoint inhibitors in the treatment of advanced urothelial carcinoma and then suggest how they can be sequenced in the context of available chemotherapeutic options. For cisplatin-eligible patients, platinum-based chemotherapy remains the standard first-line treatment. For patients progressing on platinum-based therapy, phase III trials have been performed comparing pembrolizumab and atezolizumab separately with standard chemotherapy, and results favor the use of pembrolizumab.https://doi.org/10.1177/1758835918788310 |
| spellingShingle | Pooja Ghatalia Matthew Zibelman Daniel M. Geynisman Elizabeth Plimack Approved checkpoint inhibitors in bladder cancer: which drug should be used when? Therapeutic Advances in Medical Oncology |
| title | Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
| title_full | Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
| title_fullStr | Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
| title_full_unstemmed | Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
| title_short | Approved checkpoint inhibitors in bladder cancer: which drug should be used when? |
| title_sort | approved checkpoint inhibitors in bladder cancer which drug should be used when |
| url | https://doi.org/10.1177/1758835918788310 |
| work_keys_str_mv | AT poojaghatalia approvedcheckpointinhibitorsinbladdercancerwhichdrugshouldbeusedwhen AT matthewzibelman approvedcheckpointinhibitorsinbladdercancerwhichdrugshouldbeusedwhen AT danielmgeynisman approvedcheckpointinhibitorsinbladdercancerwhichdrugshouldbeusedwhen AT elizabethplimack approvedcheckpointinhibitorsinbladdercancerwhichdrugshouldbeusedwhen |